The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Risankizumab & Apremilast Come to Market in Canada

Risankizumab & Apremilast Come to Market in Canada

March 9, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
  • Risankizumab Promising for Psoriasis; Plus Canada Approves Brodalumab
  • Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis
Explore This Issue
April 2020
Also By This Author
  • New Data Highlight Effectiveness of Guselkumab for Patients with PsA

In Canada, five provinces will now reimburse patients with plaque psoriasis who use risankizumab. Also, Health Canada recently approved apremilast for treating adults with plaque psoriasis and active psoriatic arthritis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Public Reimbursement for Risankizumab
In February, risankizumab (Skyrizi) was officially listed on the formularies of four Canadian provinces (Ontario, Alberta, Saskatchewan and Quebec) for treating adults with moderate to severe plaque psoriasis, making it eligible for public reimbursement.1 Risankizumab was also recently added to the Nova Scotia formulary.2

According to the drug’s manufacturer, AbbVie, this announcement was made two months after the pan-Canadian Pharmaceutical Alliance (pCPA) approved the treatment. Risankizumab is the only interleukin 23 inhibitor to receive a positive conclusion from pCPA, and it is listed on the Alliance’s formularies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In clinical studies, risankizumab significantly improved skin clearance after 16 weeks of therapy and maintained skin clearance through one year. One million, or 3.1% of, Canadians are thought to have psoriasis, with approximately 325,000 Canadians considered to have moderate to severe disease.

Health Canada Approves Apremilast
Health Canada has approved apremilast, a phosphodiesterase 4 inhibitor anti-inflammatory agent, for treating adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. It can also be used as monotherapy or combined with methotrexate to treat adults with active psoriatic arthritis who have had an inadequate response, intolerance or contraindication to a prior disease-modifying anti-rheumatic drug.3 Apremilast will be available in 10, 20 and 30 mg tablets.

In clinical trials, its most common side effects were diarrhea, nausea, upper respiratory tract infection and headache. Prior to this latest approval, apremilast was approved in more than 50 markets outside of Canada, including the U.S., EU and Japan.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. AbbVie Inc. News release: AbbVie’s Skyrizi now publicly reimbursed in Ontario, Alberta, Saskatchewan and Quebec for the treatment of moderate to severe plaque psoriasis. 2020 Feb 6.
  2. AbbVie Inc. News release: BRIEF—Abbvie’s Skyrizi now listed on the Nova Scotia formulary for the treatment of moderate to severe plaque psoriasis. 2020 Feb 13.
  3. Amgen Inc. News release: Amgen Canada receives approval of marketing authorization transfer of Otezla for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. 2020 Feb 12.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: apremilast, Canada, plaque psoriasis, Psoriatic Arthritis, risankizumabIssue: April 2020

You Might Also Like:
  • IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
  • Risankizumab Promising for Psoriasis; Plus Canada Approves Brodalumab
  • Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis
  • Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.